Evidence: LowPeptide Clinical Trials Pipeline & In-Development

PB-718

also known as: PB718

PegBio's dual GLP-1 / GLP-2 agonist — an unusual combination targeting both the incretin axis and intestinal mucosal trophic signaling; Phase 2 in T2DM and NAFLD.

A long-acting dual GLP-1 / GLP-2 receptor agonist peptide developed by PegBio (Suzhou, China), in Phase 2 for type 2 diabetes and non-alcoholic fatty liver disease; an unusual dual combination that adds GLP-2 (intestinal mucosal trophic) signaling to standard GLP-1 incretin agonism, with the pharmacological rationale of protecting the intestinal barrier against GLP-1-driven GI side effects while adding direct intestinal-growth benefit.

Mechanism of action

Dual agonism at GLP-1 and GLP-2 receptors. GLP-1: standard incretin effects. GLP-2: intestinotrophic signaling — enterocyte proliferation, villous growth, tight-junction integrity — which in theory mitigates GLP-1-related GI inflammation and preserves intestinal barrier function.

Primary uses

Type 2 diabetes mellitus (Phase 2)
NAFLD/MASLD (Phase 2)

Typical dosing

once weekly (subcutaneous)

Phase 2 doses not publicly finalized.

Regulatory status

Not approved. Phase 2 in China for type 2 diabetes and NAFLD.

Status as of this entry's last review, April 19, 2026. Approvals, compounding rules and sport rules change; the regulatory tracker is checked more often.

What the studies show

PB-718 is an injectable candidate from PegBio. Its two registered trials, a phase 1 in healthy subjects and a phase 1/2 in obesity, are both completed; no paper on it is in PubMed, so no result is stated here.

Registry · 2020

Phase 1 dose escalation

A double-blind, randomised, placebo-controlled study of single and multiple escalating doses in 82 healthy subjects, completed in May 2022.

NCT05021666 · ClinicalTrials.gov record

Registry · 2023

Phase 1/2 in obesity

Weekly dose-escalated PB-718 against placebo over 12 to 18 weeks in 36 people with obesity, testing safety, tolerability and pharmacokinetics; completed in April 2024.

NCT06147544 · ClinicalTrials.gov record

References

[manufacturer] PegBio Co., Ltd. Pipeline disclosures — PB-718 dual GLP-1/GLP-2 agonist.
[clinicaltrials] ClinicalTrials.gov NCT05021666: "A Phase 1, Double-blind, Randomized, Placebo-controlled, Single- and Multiple-dose Escalating Study" PegBio Co., Ltd.. Phase 1, completed, July 2020 to May 2022 (primary completion), 82 participants. Registry record read October 2, 2026.
[clinicaltrials] ClinicalTrials.gov NCT06147544: "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-718 Injection in Chinese Obese Subjects." PegBio Co., Ltd.. Phase 1, Phase 2, completed, July 2023 to April 2024 (primary completion), 36 participants. Registry record read October 2, 2026.

Related peptides

Semaglutide

A once-weekly GLP-1 receptor agonist FDA-approved for type 2 diabetes and chronic weight management.

Teduglutide

FDA-approved GLP-2 analog (Gattex/Revestive, 2012) for short-bowel syndrome — the first disease-modifying treatment for SBS, reducing parenteral nutrition dependence by promoting intestinal mucosal growth.

Apraglutide

Ironwood's weekly GLP-2 analog for short-bowel syndrome — STARS Phase 3 positive (2024), NDA submitted to FDA 2025; potentially the first once-weekly SBS therapy and a meaningful improvement over teduglutide's daily dosing.

Guides & tools

Explore with tools

Glossary → Peptide Comparison → Cost Calculator → Beginner's Guide → All Pipeline peptides →

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.